New hope for kidney cancer? early trial of XmAb819 begins
NCT ID NCT05433142
First seen Mar 08, 2026 · Last updated May 05, 2026 · Updated 6 times
Summary
This early-phase study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug intravenously or as an injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Xencor Investigative Site
RECRUITINGPhoenix, Arizona, 85054, United States
-
Xencor Investigative Site
RECRUITINGDuarte, California, 91010, United States
-
Xencor Investigative Site
RECRUITINGSacramento, California, 95817, United States
-
Xencor Investigative Site
RECRUITINGNew Haven, Connecticut, 06520, United States
-
Xencor Investigative Site
RECRUITINGJacksonville, Florida, 32224, United States
-
Xencor Investigative Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Xencor Investigative Site
RECRUITINGChicago, Illinois, 60611, United States
-
Xencor Investigative Site
RECRUITINGChicago, Illinois, 60637, United States
-
Xencor Investigative Site
RECRUITINGLouisville, Kentucky, 40207, United States
-
Xencor Investigative Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Xencor Investigative Site
RECRUITINGNew Brunswick, New Jersey, 088901, United States
-
Xencor Investigative Site
RECRUITINGNew York, New York, 10032, United States
-
Xencor Investigative Site
RECRUITINGNew York, New York, 10065, United States
-
Xencor Investigative Site
RECRUITINGCharlotte, North Carolina, 28777, United States
-
Xencor Investigative Site
RECRUITINGDurham, North Carolina, 27710, United States
-
Xencor Investigative Site
RECRUITINGCincinnati, Ohio, 45267, United States
-
Xencor Investigative Site
RECRUITINGColumbus, Ohio, 43210, United States
-
Xencor Investigative Site
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Xencor Investigative Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Xencor Investigative Site
RECRUITINGSeattle, Washington, 98109, United States
-
Xencor Investigative Site
RECRUITINGVillejuif, 94805, France
-
Xencor Investigative Site
RECRUITINGMadrid, 28050, Spain
-
Xencor Investigative Site
RECRUITINGCambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Conditions
Explore the condition pages connected to this study.